

## Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being transmitted via facsimile to the United States Patent and Trademark Office on:

10/29/2002  
Date of Transmission

Gregory M. Zinkl, Ph.D.  
Name of Applicant, Assignee or Registered Representative

[Signature]  
Signature

10/29/2002  
Date of Signature

#16  
JM  
11/12/02

Our Case No. 9800081-0041

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	)	
Gerritsen, <i>et al.</i>	)	
Serial No.:	)	Examiner Gary B. Nickol, Ph.D.
	)	
Filing Date:	)	Group Art Unit No.: 1642
	)	
For: DIFFERENTIALLY-EXPRESSED	)	
GENES INVOLVED IN	)	
ANGIOGENESIS, THE	)	
POLYPEPTIDES ENCODED	)	
THEREBY, AND METHODS OF	)	
USING THE SAME	)	

## RESTRICTION RESPONSE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Responsive to the Official Action of August 5, 2002, Applicants elect, with traverse, Group 308, Claims 37-41, 47-48 (SEQ ID NO:2). For claim 48, Applicants further elect as a species an angiogenic agent.

## RESTRICTED GROUPS

The application has been restricted into 564 groups, divided into sets, as follows:

### **Groups 1-27 (Set 1):**

Claims 1-7, drawn to a method of assessing the efficacy of an angiogenic disorder treatment in a subject, comprising providing from the subject a test cell population capable of expressing one nucleic acid selected from PA:1-27, wherein the test cell population is provided *ex vivo* or *in vitro*, classified in class 434, subclass 6.

### **Groups 28-55 (Set 2):**

Claims 1-5, 8, drawn to a method of assessing the efficacy of an angiogenic disorder treatment in a subject, comprising providing from the subject a test cell population capable of expressing one nucleic acid selected from PA:1-27, wherein the test cell population is provided *in vivo*, classified in class 424, subclass 9.1.

### **Groups 56-83 (Set 3):**

Claims 9-15, 27-29, drawn to a method of diagnosing an angiogenic disorder in a subject, comprising providing from the subject a test cell population capable of expressing one nucleic acid selected from PA:1-27, wherein the test cell population is provided *in vitro* or *ex vivo*, classified in class 424, subclass 9.1.

### **Groups 84-111 (Set 4):**

Claims 9-13, 16, drawn to a method of diagnosing an angiogenic disorder in a subject, comprising providing from the subject a test cell population capable of expressing one nucleic acid selected from PA:1-27, wherein the test cell population is provided *in vivo*, classified in class 424, subclass 9.1.

### **Groups 112-139 (Set 5):**

Claims 17-26, drawn to a method of identifying a test therapeutic agent for treating an angiogenic disorder in a subject, comprising contact with a test therapeutic agent and providing from the subject a test cell population capable of expressing one nucleic acid selected from PA:1-27, classified in class 424, subclass 9.2.

### **Groups 140-167 (Set 6):**

Claims 30-34, drawn to a method of treating an angiogenic disorder, comprising administering to a patient an agent that modulates the expression or activity of one nucleic acid selected from PA:1-27, wherein said agent is an antisense molecule, classified in class 514, subclass 44.

**Groups 168-195 (Set 7):**

Claims 30-34, drawn to a method of treating an angiogenic disorder, comprising administering to a patient an agent that modulates the expression or activity of one nucleic acid selected from PA:1-27, wherein said agent is selected from the group consisting of a peptide, a PA polypeptide agonist, a PA polypeptide antagonist, or a peptidomimetic, classified in class 424, subclass 184.1.

**Groups 196-223 (Set 8):**

Claims 30-34, drawn to a method of treating an angiogenic disorder, comprising administering to a patient an agent that modulates the expression or activity of one nucleic acid selected from PA:1-27, wherein said agent is selected from the group consisting of a small molecule or other drug, classified in class 514, subclass 1.

**Groups 224-251 (Set 9):**

Claims 30-34, drawn to a method of treating an angiogenic disorder, comprising administering to a patient an agent that modulates the expression or activity of one nucleic acid selected from PA:1-27, wherein said agent is selected from the group consisting of an antibody, classified in class 424, subclass 130.1.

**Groups 252-279 (Set 10):**

Claim 35, drawn to a kit, comprising one or more reagents for detecting one nucleic acid sequences selected from the group consisting of PA:1-27, classified in class 435, subclass 810.

**Groups 280-307 (Set 11):**

Claims 36, 42-46, 49-50, drawn to an isolated nucleic acid probe to detect one nucleic acid sequence of PA:1-27, isolated nucleic acids with at least 75% identity to one nucleic acid of PA:1-27, and one therapeutic composition thereof including additional active ingredients, classified in class 536, subclass 23.5; class 514, subclass 44.

**Groups 308-335 (Set 12):**

Claims 37-41, 47-48, drawn to an isolated polypeptide at least 80% identical to one polypeptide, comprising an amino acid sequence of PA:1-27, and one therapeutic compositions thereof, including additional active ingredients, classified in class 530, subclass 350; class 514, subclass 2.

**Groups 336-363 (Set 13):**

Claims 51-52, drawn to one therapeutic agonist or antagonist of a PA polypeptide and an additional active ingredient, classified in class 514, subclass 1.

**Groups 364-391 (Set 14):**

Claims 53, drawn to a kit, comprising one therapeutic composition selected from the group consisting of one PA polypeptide, or one agonist of a PA polypeptide or one antagonist of a PA polypeptide, classified in class 435, subclass 810.

**Groups 392-419 (Set 15):**

Claim 54, drawn to a method of treating an angiogenic disorder, comprising administering one therapeutic compound, comprising one polypeptide, classified in class 424, subclass 184.1.

**Groups 420-447 (Set 16):**

Claim 55, drawn to a method of treating an angiogenic disorder, comprising administering one therapeutic compound, comprising one nucleic acid molecule, classified in class 514, subclass 44.

**Groups 448-475 (Set 17):**

Claim 56-57, drawn to a method for inhibiting angiogenesis in a mammal, comprising administering one PA polypeptide, or one agonist of a PA polypeptide or one antagonist of a PA polypeptide, classified in class 424, subclass 184.1.

**Groups 476-503 (Set 18):**

Claim 58-59, drawn to a method for stimulating angiogenesis in a mammal, comprising administering one PA polypeptide, or one agonist of a PA polypeptide or one antagonist of a PA polypeptide, classified in class 424, subclass 184.1.

**Groups 504-531 (Set 19):**

Claim 56-57, drawn to a method for inhibiting angiogenesis in a mammal, comprising administering one anti-PA antibody, classified in class 424, subclass 130.1.

**Groups 532-559 (Set 20):**

Claim 58-59, drawn to a method for stimulating angiogenesis in a mammal, comprising administering one anti-PA antibody, classified in class 424, subclass 130.1

**Group 560 (Set 21):**

Claims 60-62, 65, drawn to an isolated nucleic acid molecule, comprising a nucleic acid sequence at least 75% identical to a nucleic acid sequence encoding the polypeptide of SEQ ID NO:72, a vector thereof, a host cell thereof, and a pharmaceutical composition thereof, classified in class 536, subclass 23.5; class 435, subclasses 320.1, 325; class 514, subclass 44.